SCHEMBL2140294

SCHEMBL2140294

COCCCOc1cc(C[C@H](C(=O)O)C(C)C)ccc1OC

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.55
REN P00797 18/20 0.54
PPARA Q07869 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811494 1.00 LDHA (0.55) LDHARENPPARA
SCHEMBL2137730 1.00 LDHA (0.55) LDHARENPPARA
SCHEMBL14788425 0.90 PPARG (0.49) RENPPARA
SCHEMBL14778723 0.89 PPARD (0.53) LDHARENPPARA
SCHEMBL15184372 0.89 REN (0.55) REN
SCHEMBL14778721 0.89 REN (0.55) REN
SCHEMBL14777725 0.87 LDHA (0.49) LDHARENPPARA
SCHEMBL14777723 0.87 REN (0.53) REN
SCHEMBL4456020 0.86 REN (0.54) REN
SCHEMBL4456027 0.86 REN (0.54) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103207247-A Method of separating and determining aliskiren intermediate and optical isomers thereof by using liquid chromatography BEIJING WANQUAN DEZHONG MEDICAL BIOLOG TECHNOLOGY CO LTD 2013-07-17 CN disclosed
CN-101120010-B Metallocene-based phosphorus chiral phosphines SOLVIAS AG 2013-07-03 CN disclosed
US-7935841-B2 Bisphospholanes for use as catalysts in asymmetric reactions DR. REDDY'S LABORATORIES LIMITED (IN) 2011-05-03 US disclosed
US-7935841-B2 Bisphospholanes for use as catalysts in asymmetric reactions DR. REDDY'S LABORATORIES LIMITED (IN) 2011-05-03 US disclosed
US-7906669-B2 Metallocene-based phosphorus chiral phosphines SOLVIAS AG (CH) 2011-03-15 US disclosed
EP-1844061-B1 METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES SOLVIAS AG (CH) 2010-08-04 EP disclosed
US-20090137824-A1 METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES PHOENIX CHEMICALS LTD (GB) 2009-05-28 US disclosed
US-20090099358-A1 BISPHOSPHOLANES FOR USE AS CATALYSTS IN ASYMMETRIC REACTIONS JACKSON PHILIP M 2009-04-16 US disclosed
US-20090099358-A1 BISPHOSPHOLANES FOR USE AS CATALYSTS IN ASYMMETRIC REACTIONS JACKSON PHILIP M 2009-04-16 US disclosed
US-20080242876-A1 Process For the Manufacture of Substituted Propionic Acids PHOENIX CHEMICALS LTD. (GB) 2008-10-02 US disclosed
CN-101133011-A Process for the manufacture of substituted propionic acids PHOENIX CHEMICALS LTD (GB) 2008-02-27 CN disclosed
CN-101120010-A Metallocene-based phosphorus chiral phosphines PHOENIX CHEMICALS LTD (GB) 2008-02-06 CN disclosed
WO-2007123957-A2 BISPHOSPHOLANES FOR USE AS CATALYSTS IN ASYMMETRIC REACTIONS DOW GLOBAL TECHNOLOGIES INC. (US) 2007-11-01 WO disclosed
EP-1844061-A1 METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES Phoenix Chemicals Limited (GB) 2007-10-17 EP disclosed
EP-1838654-A1 PROCESS FOR THE MANUFACTURE OF SUBSTITUTED PROPIONIC ACIDS Phoenix Chemicals Limited (GB) 2007-10-03 EP disclosed
WO-2006075166-A1 METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES PHOENIX CHEMICALS LTD. (GB) 2006-07-20 WO disclosed
WO-2006075177-A1 PROCESS FOR THE MANUFACTURE OF SUBSTITUTED PROPIONIC ACIDS PHOENIX CHEMICALS LTD. (GB) 2006-07-20 WO disclosed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 EP disclosed
EP-0678503-A1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities CIBA-GEIGY AG (CH) 1995-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099358-A1 BISPHOSPHOLANES FOR USE AS CATALYSTS IN ASYMMETRIC REACTIONS BPGM, PFKFB3, PFKFB4 LDHA 870/4885REN 2130/4885PPARA 444/4885
US-20090137824-A1 METALLOCENE-BASED PHOSPHORUS CHIRAL PHOSPHINES POLL, ZNF207, ZC3HAV1L LDHA 1376/4885REN 3201/4885PPARA 164/4885
US-20080242876-A1 Process For the Manufacture of Substituted Propionic Acids AS3MT, PPA1, AGPS LDHA 268/4885REN 1227/4885PPARA 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.